← Back to All US Stocks

Vivani Medical, Inc. (VANI) Stock Fundamental Analysis & AI Rating 2026

VANI Nasdaq Electromedical & Electrotherapeutic Apparatus DE CIK: 0001266806
Recently Updated • Analysis: May 14, 2026 • SEC Data: 2026-03-31
Combined AI Rating
STRONG SELL
92% Confidence
N/A
STRONG SELL
92% Conf
Pending
Analysis scheduled

📊 VANI Key Takeaways

Revenue: $0.0
Net Margin: N/A
Free Cash Flow: $-6.2M
Current Ratio: 3.18x
Debt/Equity: 0.00x
EPS: $-0.08
AI Rating: STRONG SELL with 92% confidence
Vivani Medical, Inc. (VANI) receives a STRONG SELL rating with 92% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $0, and return on equity (ROE) of -35.5%, Vivani Medical, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete VANI stock analysis for 2026.

Is Vivani Medical, Inc. (VANI) a Good Investment?

Claude

Vivani Medical is a pre-revenue company with severe operational losses of $6.8M and negative operating cash flow of $6.2M, indicating unsustainable burn with no demonstrated commercial traction. Despite holding $19.7M in cash and zero debt, the company will deplete resources within 3-4 years at current burn rates unless revenue materializes immediately. The complete absence of revenue in a medical device company raises fundamental questions about product viability and market acceptance.

Why Buy Vivani Medical, Inc. Stock? VANI Key Strengths

Claude
  • + Strong cash position of $19.7M provides 3-4 year operational runway
  • + Zero debt eliminates refinancing risk and provides financial flexibility
  • + Excellent liquidity ratios (3.18x current, 3.14x quick) ensure near-term solvency

VANI Stock Risks: Vivani Medical, Inc. Investment Risks

Claude
  • ! Zero revenue indicates complete absence of commercial traction or product-market fit
  • ! Operating cash burn of $6.2M annually is unsustainable without revenue offsetting costs
  • ! Medical device sector requires significant capital investment with no guarantee of regulatory approval or market adoption
  • ! Negative ROE (-35.5%) and ROA (-16.0%) demonstrate systematic destruction of shareholder and asset value
  • ! Cash depletion timeline creates existential threat if revenue generation does not occur within 3-4 years

Key Metrics to Watch

Claude
  • * Revenue recognition - any movement from $0 is critical signal
  • * Operating cash flow trend - must turn positive to demonstrate path to profitability
  • * Monthly cash burn rate - acceleration would accelerate timeline to insolvency

Vivani Medical, Inc. (VANI) Financial Metrics & Key Ratios

Revenue
$0.0
Net Income
$-6.8M
EPS (Diluted)
$-0.08
Free Cash Flow
$-6.2M
Total Assets
$42.4M
Cash Position
$19.7M

💡 AI Analyst Insight

Strong liquidity with a 3.18x current ratio provides a solid financial cushion.

VANI Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE -35.5%
ROA -16.0%
FCF Margin N/A

VANI vs Healthcare Sector: How Vivani Medical, Inc. Compares

How Vivani Medical, Inc. compares to Healthcare sector averages

Net Margin
VANI 0.0%
vs
Sector Avg 12.0%
VANI Sector
ROE
VANI -35.5%
vs
Sector Avg 15.0%
VANI Sector
Current Ratio
VANI 3.2x
vs
Sector Avg 2.0x
VANI Sector
Debt/Equity
VANI 0.0x
vs
Sector Avg 0.6x
VANI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Vivani Medical, Inc. Stock Overvalued? VANI Valuation Analysis 2026

Based on fundamental analysis, Vivani Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-35.5%
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Vivani Medical, Inc. Balance Sheet: VANI Debt, Cash & Liquidity

Current Ratio
3.18x
Quick Ratio
3.14x
Debt/Equity
0.00x
Debt/Assets
54.9%
Interest Coverage
N/A
Long-term Debt
N/A

VANI Revenue & Earnings Growth: 5-Year Financial Trend

VANI 5-year financial data: Year 2018: Revenue $8.0M, Net Income N/A, EPS N/A. Year 2019: Revenue $6.9M, Net Income N/A, EPS N/A. Year 2020: Revenue $3.4M, Net Income N/A, EPS N/A. Year 2024: Revenue $0, Net Income -$25.7M, EPS $-0.50. Year 2025: Revenue $0, Net Income -$23.5M, EPS $-0.43.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Vivani Medical, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-0.43 indicates the company is currently unprofitable.

VANI Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

VANI Quarterly Earnings & Performance

Quarterly financial performance data for Vivani Medical, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q2 2025 N/A -$5.4M $-0.10
Q1 2025 N/A -$6.0M $-0.11
Q3 2024 N/A -$5.4M $-0.11
Q2 2024 N/A -$5.4M $-0.10
Q2 2021 N/A -$2.3M N/A
Q3 2020 $472.0K -$1.6M N/A
Q2 2020 $1.3M -$3.1M N/A
Q1 2020 $1.1M -$8.9M N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Vivani Medical, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$6.2M
Cash generated from operations
Stock Buybacks
$123.7K
Shares repurchased (TTM)
Capital Expenditures
$3.0K
Investment in assets
Dividends
None
No dividend program

VANI SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Vivani Medical, Inc. (CIK: 0001266806)

📋 Recent SEC Filings

Date Form Document Action
May 13, 2026 8-K vani-20260513.htm View →
May 13, 2026 10-Q vani-20260331.htm View →
Apr 29, 2026 DEF 14A vani-20251231.htm View →
Apr 16, 2026 4 xslF345X06/primary_doc.xml View →
Mar 26, 2026 8-K vani-20260326.htm View →

Frequently Asked Questions about VANI

What is the AI rating for VANI?

Vivani Medical, Inc. (VANI) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.

What are VANI's key strengths?

Claude: Strong cash position of $19.7M provides 3-4 year operational runway. Zero debt eliminates refinancing risk and provides financial flexibility.

What are the risks of investing in VANI?

Claude: Zero revenue indicates complete absence of commercial traction or product-market fit. Operating cash burn of $6.2M annually is unsustainable without revenue offsetting costs.

What is VANI's revenue and growth?

Vivani Medical, Inc. reported revenue of $0.0.

Does VANI pay dividends?

Vivani Medical, Inc. does not currently pay dividends.

Where can I find VANI SEC filings?

Official SEC filings for Vivani Medical, Inc. (CIK: 0001266806) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is VANI's EPS?

Vivani Medical, Inc. has a diluted EPS of $-0.08.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is VANI a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, Vivani Medical, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is VANI stock overvalued or undervalued?

Valuation metrics for VANI: ROE of -35.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy VANI stock in 2026?

Our dual AI analysis gives Vivani Medical, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is VANI's free cash flow?

Vivani Medical, Inc.'s operating cash flow is $-6.2M, with capital expenditures of $3.0K.

How does VANI compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -35.5% (avg: 15%), current ratio 3.18 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% DT 92% DECK 92% DAVEW 92% CTAS 92% CRUS 92% CRMD 92% CRDO 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 14, 2026 | Data as of: 2026-03-31 | Powered by Claude AI